GV20 Therapeutics

GV20 Therapeutics is a biotechnology company based in Cambridge, Massachusetts. Founded in 2016, the company employs 23 individuals and generates annual revenue of $50 million. GV20 focuses on the discovery and development of antibody drugs for the treatment of cancer. Their research leverages high throughput functional genomics and artificial intelligence to identify promising drug targets within cancer immunology. This process has resulted in a diverse portfolio of immuno-oncology candidates. The company's proprietary antibody drug discovery engine sets them apart in the field. This cutting-edge technology allows for a more efficient and targeted approach to developing effective cancer therapies. For more information, visit GV20 Therapeutics at gv20tx.com.